Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 diabetes is unknown. METHODS: In this phase 3b, open-label, controlled trial, adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg) subcutaneously once weekly for 72 weeks. The primary end point was the percent change in weight from baseline to week 72. Key secondary end points included weight reductions of at least 10%, 15%, 20%, and 25% and a change in waist circumference from baseline to week 72. RESULTS: A total of 751 participants underwent randomization. The least-squares mean percent change in weight at week 72 was -20.2% (95% confidence interval [CI], -21.4 to -19.1) with tirzepatide and -13.7% (95% CI, -14.9 to -12.6) with semaglutide (P<0.001). The least-squares mean change in waist circumference was -18.4 cm (95% CI, -19.6 to -17.2) with tirzepatide and -13.0 cm (95% CI, -14.3 to -11.7) with semaglutide (P<0.001). Participants in the tirzepatide group were more likely than those in the semaglutide group to have weight reductions of at least 10%, 15%, 20%, and 25%. The most common adverse events in both treatment groups were gastrointestinal, and most were mild to moderate in severity and occurred primarily during dose escalation. CONCLUSIONS: Among participants with obesity but without diabetes, treatment with tirzepatide was superior to treatment with semaglutide with respect to reduction in body weight and waist circumference at week 72. (Funded by Eli Lilly; SURMOUNT-5 ClinicalTrials.gov number, NCT05822830.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tirzepatide also leads to greater weight loss than semaglutide for people with type 2 diabetes 14 and than liraglutide for people with obesity.15”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [15]
In the citing paper
“In the STEP-8 trial, 70 semaglutide 2•4 mg/week led to greater weight loss (a 15•8% reduction) compared with liraglutide 3•0 mg once daily (a 6•4% reduction); in the SURMOUNT-5 trial, 15 tirzepatide 15 mg caused significantly higher weight reduction (20•2%) compared with semaglutide 2•4 mg (13•7%”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [15]
In the citing paper
“in the SURMOUNT-5 trial, 15 tirzepatide 15 mg caused significantly higher weight reduction (20•2%) compared with semaglutide 2•4 mg (13•7% )”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [15]
In the citing paper
“Similar differences in effectiveness are found when looking at reductions in waist circumference, systolic blood pressure, and serum triglycerides, with differences in effect sizes reflecting the differences in weight loss in response to liraglutide, semaglutide, and tirzepatide treatment.15,70”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [15]
In the citing paper
“The efficacy of GLP-1 receptor agonists (GLP-1 RAs) in older adults has been robustly demonstrated in randomized controlled trials (RCTs) [34], providing strong evidence for their use in managing obesity and related comorbidities in individuals aged over 65.”
From A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass (2026) · cites this paper as [34]
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1998) · PsycEXTRA Dataset · doi:10.1037/e565682010-001 · Cited by 9,472
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Whelton, P. K. (2002) · JAMA · doi:10.1001/jama.288.15.1882 · Cited by 1,473
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., Dunn, J. P., Chakladar, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404881 · Cited by 871
Self-citationTwo-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02026-4 · Cited by 868
Cited by
Items 101–200 of 590
Obesity and emerging intervention strategies: Mechanistic insights and novel drug targets
Feng, X., Li, S., Li, J., & Su, Z. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003919 · Cited by 7
“[98] Regulatory Mechanisms of Anti-Obesity Medications Current anti-obesity medications exert their effects by regulating different biological pathways through the central nervous system (CNS) or peripheral metabolism.”
DeParis, S. W., Oke, I., Gaier, E. D., Moss, H. E., MacIntosh, P. W., Gilbert, A. L., Dinkin, M., & Chen, J. J. (2026) · Ophthalmology · doi:10.1016/j.ophtha.2026.04.008 · Cited by 10
Weight management treatment in obesity
Rubio, M. Á., & Carreiro, S. M. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107152 · Cited by 7
Obesity and Weight Management in HIV: Epidemiology, Complications, and Emerging Treatments
Pryke, L. A., Koethe, J. R., & Bailin, S. S. (2026) · Current HIV/AIDS Reports · doi:10.1007/s11904-026-00776-1 · Cited by 13
Obesity as a modifiable risk factor in patients with chronic kidney disease
Morales, E., Jenssen, T. G., Bevc, S., Miglinas, M., Martin, W. P., Theodorakopoulou, M. P., Jørgensen, M. B., & Trillini, M. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf231 · Cited by 10
Gastrointestinal Symptoms in Obesity Therapy: Mechanisms, Epidemiology, and Management Strategies
Witaszek, T., Biesiada, A. M., Iskra-Trifunović, J., Babicki, M., Mastalerz–Migas, A., & Kłoda, K. (2025) · Biomedicines · doi:10.3390/biomedicines13102362 · Cited by 8
“Tirzepatide appears to be better tolerated than semaglutide, which may relate to its dual GLP-1R and GIP receptor (GIPR) action [23].”
InfluentialThe Role of Exercise in the Contemporary Era of Obesity Management Medications
Jakicic, J. M., & Rogers, R. J. (2025) · Current Sports Medicine Reports · doi:10.1249/jsr.0000000000001272 · Cited by 6
From obesity to cardiovascular disease: pathological basis and clinical implications
Nardin, M., Mehran, R., Oliva, A., Kedhi, E., Galasso, G., Nardin, S., Savonitto, S., Condorelli, G., & Luca, G. D. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.04.041 · Cited by 7
Rangraze, I. R., El-Tanani, M. E.-T., Janež, A., Maggio, V., Rabbani, S. A., Jensterle, M., Munda, A., Abbas, E. E., Ali, H. S., Farooqi, M. R., et al. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01868-2 · Cited by 5
Nordestgaard, L. T., Luo, J., Emanuelsson, F., Leyden, G. M., Sanderson, E. C. M., Smith, G. D., Christoffersen, M., Afzal, S., Benn, M., Nordestgaard, B. G., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf662 · Cited by 6
Real-world effects of incretin-based Obesity medications on body composition
Bhatti, R., Sadiya, A., Mussa, B. M., Khan, R., & Abusnana, S. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100229 · Cited by 7
Monzo, L., Savarese, G., Duarte, K., Baudry, G., Petrie, M. C., & Girerd, N. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag042 · Cited by 6
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70167 · Cited by 5
Bril, F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70553 · Cited by 7
CVOT Summit Report 2025: advances along the cardiovascular–kidney–metabolic disease continuum
Schnell, O., Agarwal, A., Azizi, M., Ballwieser, D. A., Barnard-Kelly, K. D., Battelino, T., Blüher, M., Bugianesi, E., Cebrián, A., Ceriello, A., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03140-0 · Cited by 6
A real-world study of tirzepatide for weight loss in adults without diabetes mellitus
Angelopoulos, N., Androulakis, I. P., Rizoulis, A. A., Boniakos, A., Fousteris, E., Mentzelopoulou, V., Petkova, V. B., Paparodis, R. D., Zianni, D., Florakis, D., et al. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01986-0 · Cited by 9
O’Connor, R. M. (2026) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2026.1805953 · Cited by 6
Ellberg, C. C., Schwartz, H. R., Witt, A., McCowen, K. C., Fuentes, A. L., & Malhotra, A. (2025) · Current Pulmonology Reports · doi:10.1007/s13665-025-00384-1 · Cited by 6
Jabbar, A. B. A., Naeem, U., Zulfiqar, K., Ahmed, S., Hinkamp, C. A., Inam, M., Minhas, A. M. K., Slipczuk, L. N., Krittanawong, C., Sahebkar, A., et al. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01355-2 · Cited by 5
Obesity and Cardiovascular Disease: Mechanistic Insights and Nutritional Management Strategies
Grossman, E. (2025) · Nutrients · doi:10.3390/nu17142281 · Cited by 6
Manyari, Á. A. O., Alvarez, A. L. A., Manyari, J. D. O., Gonzalez, F., & Pouwels, S. (2025) · Obesity Surgery · doi:10.1007/s11695-025-08414-2 · Cited by 10
Barazzoni, R., Monami, M., Buscemi, S., Busetto, L., Luca, M. D., Navarra, G., Ragghianti, B., Silverii, G. A., Belluzzi, A., Mannucci, E., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70204 · Cited by 7
Paternò, V., Geraci, G., Piticchio, T., Moli, R. L., Burgio, S., Costanzo, G., Sambataro, G., Baratta, R., Barbagallo, F., & Pallotti, F. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1700894 · Cited by 9
Gosavi, R., Rasooli, M. A., Leon, N., Sivayogan, K., Koh, D., Hong, J. T., Narasimhan, V., & Ooi, G. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01405-1 · Cited by 3
Advances in incretin-based drug discovery in 2025
Müller, T. D. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01219-4 · Cited by 4
GLP-1 receptor agonists in asthma: targeting metabolic-inflammatory crossroads
O’Brien, H., Franciosi, A. N., & Butler, M. W. (2026) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001249 · Cited by 3
Javidi, D. J., Webb, D., Tartera, H. O. D., Ud‐din, M., Elias, K., Sundbom, M., & Hellström, P. M. (2025) · Neurogastroenterology & Motility · doi:10.1111/nmo.70163 · Cited by 3
Cosmetic Considerations of Semaglutide
Baggett, A. D., Saadi, C. C., Saadi, R. A., & Patel, V. (2025) · Cosmetics · doi:10.3390/cosmetics12050221 · Cited by 6
Ilie, I. R. P., Ghibu, S., Butucă, A., Dobrea, C. M., Frum, A., Homorodean, C., Chiş, A. A., & Morgovan, C. (2026) · Pharmaceuticals · doi:10.3390/ph19060876 · Cited by 7
Metformin Boosts Intestinal Lipid Sensing via GIP to Suppress Feeding
Kuah, R., Wang, M. T., Yang, Z., Back, G., Li, R., Bruce, K., LoChoy, J. N., Beaudry, J. L., Barros, D. R., Zhang, S., et al. (2025) · Diabetes · doi:10.2337/db25-0100 · Cited by 5
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101445 · Cited by 12
Angelopoulos, N., Zianni, D., Livadas, S., Androulakis, I., Fousteris, E., Paparodis, R. D., Petkova, V., Florakis, D., Mouslech, Z., Rizoulis, A. A., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70810 · Cited by 6
Simancas‐Racines, D., Campuzano-Donoso, M., Rossetti, G., Cobellis, L., Pilone, V., Fascì-Spurio, F., Gavilanes, D. J., Soria, C., Reytor-González, C., & Schiavo, L. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100290 · Cited by 3
Polu, P. R. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100686 · Cited by 7
Zufry, H., & Hariyanto, T. I. (2026) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2026.02.002 · Cited by 9
Park, S.-H., Ma, G., Park, S. J., Yang, S.-B., Seo, M., Lee, J.-H., Kweon, S., & Park, J. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123903 · Cited by 7
Lang, K. (2026) · BMJ · doi:10.1136/bmj-2026-102036 · Cited by 3
Zambrano-Villacres, R., Campuzano-Donoso, M., Reytor-González, C., Rossetti, G., Cobellis, L., Cobellis, F., Pilone, V., Simancas‐Racines, D., & Schiavo, L. (2026) · Nutrients · doi:10.3390/nu18111751 · Cited by 9
Meyer, K., McVeigh, M., Chiara, A. N., Boss, K. C., Pomfret, T. C., Semmel, K., Bacon, R., Nicolas, D., Clements, K. M., Alper, C. J., et al. (2026) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.32.3.271 · Cited by 7
Muscle-preserving therapies in the era of pharmacological weight loss
Conte, C. (2026) · Obesity and Endocrinology · doi:10.1093/obendo/wjaf020 · Cited by 7
Coca, A., Sanchez, R., SALAZAR, D. I. M. D., Peñaherrera, E., Alcocer, L., Barbosa, E., Grassi, G. M., López-Jaramillo, P. A., Lurbe, E., Parra-Carrillo, J. Z., et al. (2026) · Journal of Hypertension · doi:10.1097/hjh.0000000000004290 · Cited by 4
Aronne, L. J., Horn, D. B., Kokkinos, A. D., Falcón, B. L., Wang, H., Hoffmann, H. T., Lee, C. J., & Dunn, J. P. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.03.010 · Cited by 5
Self-citationNovel Strategies to Conquer Residual Adiposity Risk in Cardiovascular Disease
Philip, J. S., Shah, A., & Avenatti, E. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01331-w · Cited by 3
Demidova, T. Y., & Izmaylova, M. Y. (2025) · FOCUS Endocrinology · doi:10.62751/2713-0177-2025-6-3-03 · Cited by 8
Weight Loss With GLP ‐1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta‐Analysis
Lim, M. W., Gokhale, P., Akosah, A. A., & Zapata, L. V. (2026) · Obesity · doi:10.1002/oby.70169 · Cited by 6
Ciudin, A., Sapin, H., Fan, L., Dimitriadis, G. K., Zimner‐Rapuch, S., Curteis, T., Clark, L. J., Rubinstein, M., & Johansson, E. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03523-5 · Cited by 9
Autoimmunity, diet and autophagy
Blaise, S. A., & Muller, S. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.104040 · Cited by 3
Banji, D., Alshahrani, S., Alfarhan, M., & Banji, O. J. F. (2025) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-025-00050-2 · Cited by 4
Zhang, S., Niu, S., An, S., Cai, X., & Lao, X. Q. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178587 · Cited by 5
Hu, W., Gu, M., Li, H., Li, H., Kan, J., Zhang, L., Ding, Q., & Zhu, Y. Z. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100125 · Cited by 5
Pharmacological management of sleep apnea and obesity, a new frontier
Taweesedt, P. T., Orakpo, N., & Pelayo, R. (2025) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.11798 · Cited by 3
Haass‐Koffler, C. L. (2026) · Addiction · doi:10.1111/add.70374 · Cited by 3
Guo, C., Luo, T., Dong, Y., Lu, J., Xu, Z., Bian, J., Feng, X., Chen, A., Chen, D., & Feng, J. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109370 · Cited by 3
Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy
Mandour, M. O., Stears, A. J., van der Klaauw, A. A., Flanagan, C., Gaff, L., Jenkins, C., & Savage, D. B. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag126 · Cited by 4
Dâmaso, A. R., Corgosinho, F. C., Masquio, D. C. L., Figueiredo, N., Kattah, F. M., Cercato, C., Tock, L., & Campos, R. M. D. S. (2026) · Obesity Reviews · doi:10.1111/obr.70093 · Cited by 7
Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes
Pillai, A. A., Sharma, A. M., Krayem, H., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001139 · Cited by 3
Dysfunctional adipose tissue–lymphatic crosstalk in obesity
Nardo, W. D., Chan, A. Y., Porter, C. J. H., Cao, E., & Trevaskis, N. L. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01243-y · Cited by 9
The role of weight management in sleep disordered breathing
Griffin, W., le Roux, C. W., Heneghan, H., O'Shea, D. B., & Garvey, J. (2025) · Breathe · doi:10.1183/20734735.0182-2025 · Cited by 4
Crispino, S. P., Nusca, A., Ferro, A., Cricco, R., Ciancio, M., Segreti, A., Cavallari, I., Sabatino, M., Potena, L., Ussia, G. P., et al. (2025) · Biomolecules · doi:10.3390/biom15111574 · Cited by 6
Khalil, H. A., Hassanein, N. A., El-Yazbi, A. F., & Mahgoub, H. (2026) · BMC Chemistry · doi:10.1186/s13065-025-01716-7 · Cited by 4
Aranaz, P., Clavel-Millan, M., Gil‐Cardoso, K., González-Arceo, M., Hernández-González, D., Les, F., Salles, J., Amri, E., Arbonés-Mainar, J. M., Atgié, C., et al. (2025) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-025-01130-6 · Cited by 5
Is weight cycling clinically harmful?
Magkos, F., & Stefan, N. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00037-9 · Cited by 4
Frey, S., Louis-Gaubert, C., Thouzeau, A., Cossé, L., Lorant, V., Prieur, X., Flet, L., Cariou, B., Blanchard, C. L., & May, C. L. (2025) · Obesity · doi:10.1002/oby.70003 · Cited by 2
Exploring Adults’ Experiences with Tirzepatide for Weight Loss: A Mixed-Methods Study
Adam, S., Ibrahim, F. M., Dabou, E. A. R., Pitre, S., Aiman, R., & AbdelSamad, S. (2025) · Healthcare · doi:10.3390/healthcare13233102 · Cited by 4
Onoiu, A.-I., Cambra-Cortés, V., Jiménez-Franco, A., Hernández‐Aguilera, A., Parada, D., Riu, F., Antonio Zorzano, A., Camps, J., & Joven, J. (2025) · Biomolecules · doi:10.3390/biom15081112 · Cited by 5
Current clinical application of incretin therapy for obesity management
Skinner, K., & Clements, J. N. (2025) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0152 · Cited by 5
Elbashir, R. M. A., Elbashir, A., Basake, R. U., Mohieldin, A. Z. A., Elhaj, N. A. E., Ebrahim, F. E. M., Ahmed, W. G., & Mahgoub, O. A. M. (2025) · Cureus · doi:10.7759/cureus.95938 · Cited by 3
Dziewierz, A., & Siudak, Z. (2026) · Nutrients · doi:10.3390/nu18111761 · Cited by 3
“The most successful weight-loss trials to date—including the STEP program for semaglutide [9] and the SURMOUNT program for tirzepatide [13]—have incorporated intensive lifestyle interventions as a core component of the trial protocol, modeled on the structured behavioral curricula pioneered by the…”
Ong, S. S. Y., & Pasquel, F. J. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.26336 · Cited by 2
Belančić, A. (2025) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.70130 · Cited by 3
Xu, X., Zhang, Y., Geng, Y., Luo, Y., & Sun, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1650200 · Cited by 5
Teli, B., Somani, S., Arya, V., Rajput, P. J., Kahale, P., Bharmal, V. S., Shah, S., Patel, V., Ahuja, A., & PATANGE, S. A. (2026) · Cureus · doi:10.7759/cureus.108999 · Cited by 2
Bariatric Surgery in the Era of GLP1RA: A Narrative Review
Muhundan, M., & Dash, S. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03494-7 · Cited by 2
Sathambihai, T., Mathur, K., & Siddavaram, S. (2025) · Cureus · doi:10.7759/cureus.97410 · Cited by 2
Belančić, A., Şener, Y. Z., Vučković, M., Blais, J. E., Fajkić, A., Sher, E. K., Radić, M., & Radić, J. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70378 · Cited by 4
More than a sidekick: GIP signalling and cardiovascular outcomes
Kurt, B., & Kahles, F. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf944 · Cited by 3
Wharton, S., Stefański, A., Chen, J., Rao, G. S., Twum, E. A., & Denning, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71032 · Cited by 3
Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives
Fu, L., Ding, R., Xu, G., Hu, J., & Yang, P. C. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156594 · Cited by 6
Pharmacological treatment of MASH
Stefan, N., & Targher, G. (2026) · Diabetologia · doi:10.1007/s00125-026-06796-1 · Cited by 6
Rega, M., Petraglia, F. M., D’Ursi, L., Buonocore, M., Criscuolo, D., & Santoro, A. (2026) · Clinical bioenergetics · doi:10.3390/clinbioenerg2010005 · Cited by 2
Liu, L., Chen, J., Zhang, X., Zhu, S., Dai, T., Wu, Q., & Fang, Y. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-02064-1 · Cited by 3
Wu, J., Lin, Y., Hsu, W., Liu, T.-H., Tsai, Y., Huang, P., Chuang, M.-H., Yu, T., & Lai, C. (2026) · Hepatology International · doi:10.1007/s12072-025-11021-z · Cited by 3
Baig, S. J., Bhasker, A. G., Parmar, C. D., Wadhawan, R., Shah, S., Shaikh, S. S., Kapoor, N., Das, S., Harikumar, K., Kotwal, N., et al. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08669-3 · Cited by 3
Self-citationWu, J., Lee, K.-W., Huang, S.-C., Chang, H.-Y., & Lin, Y. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113273 · Cited by 2
Glucagon‐Like Peptide‐1 Receptor Agonist Utilization Among Sleep Surgery Clinic Patients
Kutler, R. B., Lin, A., Zhang, L., Trackey, P., Rivera‐Diaz, A., Jelić, S., St‐Onge, M., & Cai, Y. (2026) · Otolaryngology · doi:10.1002/ohn.70231 · Cited by 2
Rutledge, T. R., & Greco, R. (2026) · Heart and Mind · doi:10.4103/hm.hm-d-25-00125 · Cited by 2
Kazi, D. S., Beckman, J. A., Benjamin, R. M., Firestone, G., Johnson, J. C., McClellan, M., Meltzer, N., Oxrider, A., Rosen, S. E., Scott, B. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001442 · Cited by 4
Cetiner, S. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s594898 · Cited by 7
Treatment Landscape of Metabolic-Dysfunction-Associated Steatotic Liver Disease
Patel, P. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176060 · Cited by 7
Trends of obesity management in adults: an analysis across guidelines in China and in Europe
Qu, S., Bu, L., & Zhao, J. (2025) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbaf018 · Cited by 3
Wang, N., Guo, H., Song, L., Wang, J., Hu, S., Wang, M., Zhang, D., Jing, Y., Zhang, Y., Wang, M., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70571 · Cited by 5
Nowak, K., Dziewierz, A., Sojda, A., Zabojszcz, M., Szarpak, Ł., Dardzińska, N., Jaskulska, P., & Siudak, Z. (2025) · Healthcare · doi:10.3390/healthcare13222874 · Cited by 4
Barenbaum, S. R., Aras, M., Kashyap, S. R., & Aronne, L. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf641 · Cited by 2
Self-citationOstrominski, J. W., Ortega-Montiel, J., Wexler, D. J., Everett, B. M., CROMER, S. J., Byrne, C. F., Glynn, R. J., Paik, J. M., & Patorno, E. (2026) · Diabetes Care · doi:10.2337/dc25-3063 · Cited by 2
Slaton, R. M., Iranikhah, M. G., & White, C. W. (2026) · JAPhA Pharmacotherapy · doi:10.1016/j.japhar.2026.100032 · Cited by 4
Benchmarking weight loss and survival benefits after gastric bypass: a long-term cohort study
Dallal, R. M., Streitfeld, N., Haddadin, Z., Beekley, A. C., Tatarian, T., Neff, M., Kyrillos, J. V., Das, A., & Trang, A. (2026) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2025.12.007 · Cited by 3
The year in cardiovascular medicine 2025: the top 10 papers in diabetes and metabolic disorders
Cosentino, F., Marx, N., & Cannon, C. P. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehaf1125 · Cited by 2
Zhang, J., Xu, H., Dong, Y., Feng, J., & Li, R. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118024 · Cited by 2
Ketoacidosis associated with tirzepatide use in a nonobese individual without diabetes
Kemmotsu, R., Okita, T., Koike, N., Inui, R., Tabuchi, Y., & Yasuda, T. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag054 · Cited by 4
Should Incretin Agonist-Based Drugs be Considered for First Line Antihypertensive Therapy?
Kylies, D., Dreher, L., & Wenzel, U. O. (2026) · Current Hypertension Reports · doi:10.1007/s11906-026-01374-7 · Cited by 2
Metadata
- Authors
- Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Gomez Valderas, E., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., & Dunn, J. P.
- Affiliations
- Weill Cornell Medicine (US)
- University of Texas Center for Obesity Medicine and Metabolic Performance, Department of Surgery, University of Texas McGovern Medical School, Houston
- Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin
- University of California, Los Angeles (US)
- Eli Lilly, Indianapolis
- Eli Lilly (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-07-03
- Volume
- 393
- Issue
- 1
- Pages
- 26-36
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4410277932
- Cited by
- 634
- References
- 40
- Citations by year
- 2026: 448 · 2025: 186
- FWCI
- 355.83
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- eCommons (Cornell University) (submittedVersion, cc-by-nc-nd)
- Funders
- Eli Lilly and Company (NA)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- tirzepatide, semaglutide, obesity, weight loss, waist circumference, GLP-1 receptor agonists, GIP/GLP-1 receptor agonist, gastrointestinal adverse effects, non-diabetic obesity
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Adult, Aged, Body Weight, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents, Maximum Tolerated Dose, Glucagon-Like Peptide 1, Waist Circumference
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.